Scarica l'app Stockscreener
19.78
0.30%
-0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.84
Aprire:
$19.62
Volume 24 ore:
923.77K
Relative Volume:
1.12
Capitalizzazione di mercato:
$1.31B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-7.6667
EPS:
-2.58
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
-2.80%
1M Prestazione:
-5.49%
6M Prestazione:
-27.92%
1 anno Prestazione:
-41.17%
Intervallo 1D:
$18.80
$19.86
Intervallo di 1 settimana:
$18.55
$20.67
Portata 52W:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Confronta CLDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
19.78 | 1.35B | 9.98M | -154.08M | -159.66M | -2.58 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa
Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com
BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World
UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World
The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World
Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus
UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus
First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus
Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus
Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News - GuruFocus
Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Repo - GuruFocus
H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Canada
UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Report | CLDX Stock News - GuruFocus
Celldex: Q1 Earnings Snapshot - New Haven Register
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Celldex Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Revenue $695K - marketscreener.com
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 - marketscreener.com
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - Bluefield Daily Telegraph
Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX
Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus
Interesting CLDX Put And Call Options For June 20th - Nasdaq
Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - The Manila Times
New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan
Celldex Therapeutics (CLDX) Projected to Post Quarterly Earnings on Monday - Defense World
Celldex: Q4 Earnings Snapshot - Barchart.com
Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX
A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News
Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Celldex Therapeutics Inc’s results are impressive - uspostnews.com
The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com
Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):